SCHEMBL2308791

SCHEMBL2308791

CCNCCCNc1nccc2c(C)c3[nH]c4ccncc4c3cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 7/20 0.55
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
NR3C1 P04150 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TLR3 O15455 1/20 0.40
PKM P14618 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
NPC1 O15118 1/20 0.39
GMNN O75496 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2311605 0.88 KIT (0.54) KITKDM4EMEN1NR3C1POLB
Pazelliptine SCHEMBL62441 0.86 KIT (0.73) KITKDM4EMEN1NR3C1POLB
Pazelliptine SCHEMBL29376377 0.86 KIT (0.73) KITKDM4EMEN1NR3C1POLB
SCHEMBL2308783 0.86 KIT (0.59) KITKDM4EMEN1NR3C1POLB
Pazelliptine SCHEMBL1230910 0.85 KIT (0.72) KITKDM4EMEN1NR3C1POLB
Pazelliptine SCHEMBL1230570 0.84 KIT (0.71) KITKDM4EMEN1NR3C1POLB
SCHEMBL2311284 0.84 KIT (0.76) KITKDM4EMEN1NR3C1POLB
SCHEMBL2311857 0.84 KIT (0.65) KITKDM4EMEN1NR3C1POLB
SCHEMBL2310946 0.84 KIT (0.55) KITKDM4EMEN1NR3C1POLB
SCHEMBL12387163 0.83 KIT (0.61) KITKDM4EMEN1NR3C1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989467-B2 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2011-08-02 US disclosed
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054905-A1 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process RBM17, BRCA1, SMN1; SMN2 KIT 2116/4885KDM4E 2967/4885MEN1 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.